Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 3/20 | 0.55 |
| ▸ | GPR119 | Q8TDV5 | 10/20 | 0.40 |
| ▸ | FLT3 | P36888 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.36 |
| ▸ | BRAF | P15056 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL1128553 | 0.90 | CYP3A4 (0.52) | CYP3A4GPR119FLT3CYP2C9ALDH1A1 | |
| SCHEMBL4354254 | 0.89 | CYP3A4 (0.69) | CYP3A4GPR119CYP2C9NR3C1 | |
| SCHEMBL4357368 | 0.88 | CYP3A4 (0.54) | CYP3A4GPR119CYP2C9 | |
| SCHEMBL2021635 | 0.81 | CYP3A4 (0.69) | CYP3A4GPR119CYP2C9NR3C1 | |
| SCHEMBL4355586 | 0.80 | CYP3A4 (0.46) | CYP3A4FLT3CYP2C9ALDH1A1NPC1 | |
| SCHEMBL2016352 | 0.80 | CYP3A4 (0.69) | CYP3A4GPR119CYP2C9NR3C1 | |
| SCHEMBL1129044 | 0.76 | CYP3A4 (0.70) | CYP3A4GPR119CYP2C9NR3C1 | |
| SCHEMBL4326982 | 0.75 | CYP3A4 (0.77) | CYP3A4GPR119FLT3CYP2C9NR3C1 | |
| SCHEMBL1128290 | 0.75 | CYP3A4 (0.79) | CYP3A4GPR119CYP2C9NR3C1 | |
| SCHEMBL1128356 | 0.75 | CYP3A4 (0.73) | CYP3A4GPR119CYP2C9NR3C1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8188098-B2 | GPR119 receptor agonists | HOFFMANN-LA ROCHE INC. (US) | 2012-05-29 | — | — | US | disclosed |
| EP-2283019-A1 | GPR119 RECEPTOR AGONISTS | F. Hoffmann-La Roche AG (CH) | 2011-02-16 | — | — | EP | disclosed |
| US-20090286812-A1 | GPR119 Receptor Agonists | ERICKSON SHAWN DAVID | 2009-11-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286812-A1 | GPR119 Receptor Agonists | GPR119, GPR27, GPR139 | CYP3A4 1503/4885GPR119 1/4885FLT3 2186/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.